These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 29403271)

  • 21. Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease.
    Fricker M; McDonald VM; Winter NA; Baines KJ; Wark PAB; Simpson JL; Gibson PG
    Allergy; 2021 Jul; 76(7):2079-2089. PubMed ID: 33470427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait.
    David B; Bafadhel M; Koenderman L; De Soyza A
    Thorax; 2021 Feb; 76(2):188-195. PubMed ID: 33122447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
    Song JH; Lee CH; Kim JW; Lee WY; Jung JY; Park JH; Jung KS; Yoo KH; Park YB; Kim DK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2455-2464. PubMed ID: 28860740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eosinophils in COPD: just another biomarker?
    Bafadhel M; Pavord ID; Russell REK
    Lancet Respir Med; 2017 Sep; 5(9):747-759. PubMed ID: 28601554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD.
    Kang HS; Rhee CK; Kim SK; Kim JW; Lee SH; Yoon HK; Ahn JH; Kim YH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2467-2473. PubMed ID: 27757029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits and Risks of Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease Classified by Blood Eosinophil Counts.
    Saito Z; Yoshida M; Kojima A; Tamura K; Hasegawa T; Kuwano K
    Lung; 2020 Dec; 198(6):925-931. PubMed ID: 33068153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis.
    Cheng SL
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2775-2784. PubMed ID: 30233168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility.
    Zhao H; Li R; Lv Y; Dong H; Yao L; Wu Y; Xiao G; Cai S
    Clin Respir J; 2017 May; 11(3):328-336. PubMed ID: 26077165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD.
    Kostikas K; Brindicci C; Patalano F
    Curr Drug Targets; 2018; 19(16):1882-1896. PubMed ID: 29437007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary eosinophilic lung diseases.
    Rose DM; Hrncir DE
    Allergy Asthma Proc; 2013; 34(1):19-25. PubMed ID: 23406932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD.
    Negewo NA; McDonald VM; Baines KJ; Wark PA; Simpson JL; Jones PW; Gibson PG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1495-504. PubMed ID: 27445469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of inflammatory cell function by corticosteroids.
    Belvisi MG
    Proc Am Thorac Soc; 2004; 1(3):207-14. PubMed ID: 16113436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eosinophilic and Neutrophilic Airway Inflammation in the Phenotyping of Mild-to-Moderate Asthma and Chronic Obstructive Pulmonary Disease.
    Górska K; Paplińska-Goryca M; Nejman-Gryz P; Goryca K; Krenke R
    COPD; 2017 Apr; 14(2):181-189. PubMed ID: 27983888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Lung; 2006; 184(4):217-22. PubMed ID: 17006748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges.
    Barrecheguren M; Esquinas C; Miravitlles M
    Curr Opin Pulm Med; 2015 Jan; 21(1):74-9. PubMed ID: 25405671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
    Sridhar S; Liu H; Pham TH; Damera G; Newbold P
    Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
    Barnes PJ
    J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease.
    Zeiger RS; Tran TN; Butler RK; Schatz M; Li Q; Khatry DB; Martin U; Kawatkar AA; Chen W
    J Allergy Clin Immunol Pract; 2018; 6(3):944-954.e5. PubMed ID: 29153881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.